Genmab (GMAB) Stock Price, Fundamentals & Analysis

What GMAB does

Genmab (GMAB) is a biotechnology company headquartered in Copenhagen, Denmark, that develops antibody-based products for the treatment of cancer and other diseases. It markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory diffuse large B-cell lymphoma, large B-cell lymphoma, and follicular lymphoma, and Tivdak for adult patients with recurrent or metastatic cervical cancer. The company is also developing Epcoritamab for several lymphoma and leukemia settings, tisotumab vedotin for solid tumors, Acasunlimab for solid tumors and non-small cell lung cancer, Rinatabart Sesutecan for platinum-resistant ovarian cancer and solid tumors, and multiple investigational antibodies for solid tumors. Genmab is part of the Nasdaq Copenhagen stocks universe and is often compared with peers such as Novo Nordisk (NOVO-B) and Zealand Pharma (ZEAL).

Key numbers explained

• 2,277 DKK is the current share price, the latest traded price on the Nasdaq Copenhagen market.
• +0.4% is the price change today, showing the intraday move relative to the previous close.
• 140.01B DKK is the market capitalization, the total value of all outstanding shares.
• The trailing P/E ratio of 27.6 divides the current share price by the last 12 months of earnings per share (82.51 USD), showing how much investors pay per unit of recent earnings.
• The forward P/E ratio of 20.9 uses expected future earnings, which can be lower if the market anticipates growth.
• 0% dividend yield and 0% share of earnings paid out as dividends mean Genmab does not currently distribute cash dividends.
• 0.7 beta suggests the stock tends to move less than the overall market, a measure of volatility relative to the market.
• 24.9% revenue growth year over year on 4.13B USD trailing 12-month revenue indicates how quickly the top line is expanding.
• 19.1% profit margin and 35.2% operating margin show how much of each revenue dollar remains as profit after costs and operating expenses.
• 14% return on equity measures how effectively the company generates profit from shareholders' equity.
• 88.5% debt-to-equity ratio expresses the company's financial leverage, comparing total debt to shareholders' equity.
• 3.47 price-to-book compares the share price to the book value per share, a way to see whether the market values the company above or below its accounting net assets.

What to watch

Investors tracking Genmab may monitor upcoming catalysts such as the next earnings report on Nov 5, 2026, which can move the stock if results or guidance differ from expectations. Because Genmab operates in the biotechnology sector, developments such as clinical trial readouts, regulatory decisions, and product launches for its oncology pipeline can influence sentiment. The stock's 0.7 beta and its position among Danish healthcare peers like Coloplast (COLO-B), Ambu (AMBU-B), and GN Store Nord (GN) may be relevant for those comparing risk and sector exposure. Broader market conditions, interest rate environments, and currency movements can also affect biotech stocks, including those listed on the Nasdaq Copenhagen.